Literature DB >> 6870524

The role of splenectomy in Gaucher's disease.

E Shiloni, D Bitran, E Rachmilewitz, A L Durst.   

Abstract

Thirteen patients underwent splenectomy for Gaucher's disease. All patients were Jewish; 12, of Ashkenazi descent, had the chronic (type 1) form, and one child, of Sephardic (Persian) origin, probably had the intermediate (type 3) form. Hypersplenism was the indication for surgery in 11 patients, mechanical problems in the remaining two. The weight of the resected spleens ranged from 1.06 to 13 kg. Following surgery, hypersplenism (thrombocytopenia in particular) was improved, and the mechanical disturbances were relieved in all patients. There were no deaths and no morbidity related to the operative procedure. Long-term follow-up demonstrated progressive hepatomegaly without evidence of hepatic dysfunction in any of the patients. Bone marrow involvement manifested by osteoarticular complications appeared in five patients. Splenectomy is, we believe, a safe mode of treatment for type 1 Gaucher's disease.

Entities:  

Mesh:

Year:  1983        PMID: 6870524     DOI: 10.1001/archsurg.1983.01390080037011

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

1.  Partial splenectomy for Gaucher's disease.

Authors:  B M Rodgers; C Tribble; A Joob
Journal:  Ann Surg       Date:  1987-06       Impact factor: 12.969

2.  Elective subtotal splenectomy. Indications and results in 33 patients.

Authors:  P C Guzzetta; E J Ruley; H F Merrick; C Verderese; N Barton
Journal:  Ann Surg       Date:  1990-01       Impact factor: 12.969

3.  Partial splenectomy for massive splenomegaly secondary to Gaucher's disease.

Authors:  W E Thomas; D A Winfield
Journal:  Postgrad Med J       Date:  1991-12       Impact factor: 2.401

Review 4.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Authors:  T M Cox; J M F G Aerts; N Belmatoug; M D Cappellini; S vom Dahl; J Goldblatt; G A Grabowski; C E M Hollak; P Hwu; M Maas; A M Martins; P K Mistry; G M Pastores; A Tylki-Szymanska; J Yee; N Weinreb
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.